Document is current
Any future updates will be listed below
-
Authors
Cope, Heidi L. https://orcid.org/0000-0003-0586-9277
Jalazo, Elizabeth R.
Berg, Jonathan S.
Sullivan, Jennifer A. https://orcid.org/0000-0002-8782-2183
Kucera, Katerina S. https://orcid.org/0000-0003-4148-6599
Shone, Scott M.
Frawley, Hannah E.
Gwaltney, Angela Y. https://orcid.org/0000-0002-2305-7187
Forsythe, Ana N.
Migliore, Brooke A.
Wright, Becca
Moultrie, Rebecca R.
Milko, Laura V. https://orcid.org/0000-0002-8060-9013
Zimmerman, Rebekah S. https://orcid.org/0000-0002-9013-1084
Kruszka, Paul
Suchy, Sharon F.
Begtrup, Amber https://orcid.org/0000-0002-2872-3281
Langley, Katherine G.
Monaghan, Kristin G.
Kraczkowski, Christina
Guenzel, Adam J.
McWalter, Kirsty https://orcid.org/0000-0002-1654-9036
Hruska, Kathleen S.
Bailey, Donald B. Jr
Wheeler, Anne C.
Raspa, Melissa https://orcid.org/0000-0003-3791-3367
Powell, Cynthia M. https://orcid.org/0000-0002-4260-5601
Peay, Holly L.
,
-
Funding
Funding for this research was provided by:
Janssen Pharmaceuticals
JDRF
Leona M. and Harry B. Helmsley Charitable Trust
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UM1TR004406, UL1TR002489, UL1TR002489, UM1TR004406, UM1TR004406, UL1TR002489, UL1TR002489)
John Merck Fund
GeneDx
- License Information
-
More Information
Article History
Received: 28 January 2025
Accepted: 6 August 2025
First Online: 5 September 2025
Competing interests
: R.S.Z., S.F.S., A.B., A.J.G., K.G.L., K.G.M., K.M., C.K., K.S.H. and P.K. were employees of GeneDx, LLC at the time of this study and may have held company stock. All RTI authors (H.L.C., K.S.K., H.E.F., A.Y.G., A.N.F., B.A.M., B.W., R.R.M., D.B.B.J., A.C.W., M.R. and H.L.P.) were supported in this research by Janssen Pharmaceuticals (July 2021 to July 2022), Breakthrough T1D (formerly JDRF International), the Leona M. and Harry B. Helmsley Charitable Trust, Travere Therapeutics and Orchard Therapeutics. UNC authors (E.R.J., J.A.S. and C.M.P.) were supported in this research by Breakthrough T1D (formerly JDRF International). The other authors declare no competing interests.
